VLS Valneva SE

VALNEVA - Declaration of shares and voting rights: Status on December 31, 2022 (corrected data) and January 4, 2023

VALNEVA - Declaration of shares and voting rights: Status on December 31, 2022 (corrected data) and January 4, 2023

VALNEVA

Declaration of shares and voting rights

Status on December 31, 2022 (corrected data) and January 4, 2023

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment A

Declaration date: January 19, 2023

Erratum: status on December 31, 2022

Number of shares

composing the share capital of Valneva		Total number of voting rights including suspended voting rights*Description of the changeDate on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 



138,367,482



 



    including:
  • 138,346,968 ordinary shares with a par value of €0.15 each; and
  • 20,514 preferred shares convertible into ordinary shares, with a par value of €0.15 each
160,933,882Exercise of 12,500 BSA equity warrant



 



Double voting rights granted on 9,775 ordinary shares		December 1st, 8 & 10, 2022



 



 



December 7, 9, 16 & 23, 2022		160,809,560

Interim status on January 4, 2023

Number of shares

composing the share capital of Valneva		Total number of voting rights including suspended voting rights*Description of the changeDate on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 



138,346,968



ordinary shares with a par value of €0.15 each





160,933,882Cancellation of 20,514 preferred shares convertible into ordinary shares, with a par value of €0.15 eachJanuary 4, 2023 i160,809,560

i Management Board decisions of January 4, 2023.

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
19/01/2023

Underlying

VLSValneva SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE
Free
VLS VALNEVA SE

VALNEVA Declaration of shares and voting rights: August 31, 2025

VALNEVA Declaration of shares and voting rights: August 31, 2025 VALNEVA Declaration of shares and voting rights August 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: September 3, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number...

September 3, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

VALNEVA Déclaration d’actions et de droits de vote : 31 août 2025

VALNEVA Déclaration d’actions et de droits de vote : 31 août 2025 VALNEVA Déclaration d’actions et de droits de vote 31 août 2025__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : 6 rue Alain Bombard, 44800 Saint-HerblainMarché réglementé Euronext Paris - Compartiment B Date de la déclaration : 3 septembre 2025 Nombre d’actions composant le capital de ValnevaNombre total de droits de vote incluant les droits de vote suspendus*Origine de la variationDate à laquelle cette variation a été const...

September 3, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Res...

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate Strong immune response after third yearly booster dose in children and adults Significant anamnestic antibody response across all six serotypesNo safety concerns observed in any age group by independent Data Monitoring Committee (DMC), consistent with previous booster results. Saint-Herblain (France), September 3rd, 2025 –  (Nasdaq: VALN; Euronext Paris: VLA) announced positive immunogenicity and safety data from the ongoing Phase 2 study of Lyme disease vaccine candidate, VLA15. ...

September 3, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva annonce de nouvelles données positives d’innocuité et d’immuno...

Valneva annonce de nouvelles données positives d’innocuité et d’immunogénicité de Phase 2 pour le candidat vaccin contre la maladie de Lyme  Forte réponse immunitaire chez les enfants et les adultes après la troisième vaccination annuelle de rappelForte réponse anamnestique observée pour les six sérotypes Aucun problème de sécurité observé dans toutes les tranches d’âge par le comité indépendant de surveillance des données (DMC), comme pour les précédents résultats de rappel Saint-Herblain (France), le 3 Septembre, 2025 –  (Nasdaq: VALN; Euronext Paris: VLA) a annoncé aujourd’hui des donné...

September 3, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vac...

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S. Saint Herblain (France), August 25, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ®, citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness. The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of IXCHIQ® in the United States. The suspension follows the FDA’s decisio...

August 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch